Please ensure Javascript is enabled for purposes of website accessibility

Why Zoetis Is the Pfizer of Animal Healthcare

By Luis Sanchez CFA - Mar 16, 2021 at 7:32AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Zoetis has proven to investors that the pharmaceutical apple doesn't fall far from the tree.

Zoetis (ZTS 1.38%) is a leader in the pharmaceutical market for pets and livestock. It used to be a part of Pfizer (PFE -0.93%), but was spun off in 2012.

What makes Zoetis's business attractive is the depth and breadth of its offerings, which include vaccines, anti-infectives, and parasiticides, serving a diverse array of pet and livestock species. This wide-ranging portfolio of blockbuster drugs is built along much the same lines as that of its former parent company, Pfizer.

Cat looking at pills on a table

Image source: Getty Images.

Zoetis's blockbuster portfolio

Zoetis defines a "blockbuster" drug as any pharmaceutical product that generates at least $100 million per year. Using that metric, the company maintains an impressive 13 blockbuster products. This blockbuster portfolio positions Zoetis as the leader among the major animal pharmaceutical companies.

Diving deeper into its leading market position: Zoetis is the No. 1 animal pharma company when it comes to companion animals (pets), livestock cattle, and fish markets. The company is No. 2 in swine and No. 3 in poultry.

Product Category 2020 2019 Year-Over-Year Change
Vaccines $1.48 billion $1.48 billion (0%)
Anti-infectives $1.21 billion $1.25 billion (4%)
Parasiticides $1.17 billion $966 million 21%
Dermatology $941 million $770 million 22%
Other pharmaceuticals $821 million $780 million 5%

Data Source: Zoetis financial reports.

Overall, Zoetis has over 300 product lines on the market today, and it's still growing. Much like Pfizer, Zoetis dominates its core markets, offering multiple brands that earn billions per year. Granted, the human health market is significantly larger than its animal counterpart -- but for Zoetis, this also means less competition from other drug makers.

Generic competition coming

That said, there are some potential bumps in the road ahead. Zoetis has long enjoyed the success of its blockbuster portfolio, but as with the human pharma market, patents don't last forever. Draxxin, one of the company's high-earning livestock products, has recently gone off-patent. The company has noted that as generic competition arrives, it expects Draxxin's sales to decline by as much as 20% to 40% in the coming years.

Luckily for Zoetis shareholders, no single product accounts for more than 10% of revenue. This means that a drug like Draxxin going off-patent won't completely alter the company's financial performance, although it can still have an impact.

As with many things in life, the best strategy is diversification. Zoetis will continue to face generic competition in some of its drugs, but it doesn't have all of its eggs in one basket.

Strong drug pipeline

Innovation is a key factor in supporting Zoetis's future growth. The company develops and maintains a drug pipeline, with an average top product age of 29 years. It also consistently releases new products and makes improvements. This is illustrated by the more than 1,100 new products and enhancements to existing products introduced in the past five years.

Zoetis's pipeline also holds significant blockbuster potential. Last year, the company released Simparica Trio, a "triple threat" parasiticide that protects against heartworm disease, kills ticks and fleas, and treats and prevents hookworms and roundworms. This is the first product to combine protection for fleas, ticks, and heartworms in one treatment. Trio brought in $150 million in net revenue in its first year despite the pandemic.

Looking to future products, Zoetis plans to introduce Librela and Solensia later this year. These two drugs, the first of their kind, use long-acting monoclonal antibodies to treat pain associated with osteoarthritis in cats and dogs. Solensia is the first osteoarthritis treatment for felines to ever go to market, and management expects both Librela and Solensia to become blockbuster products.

The Pfizer of animal healthcare

For growth investors eyeing the animal healthcare industry, Zoetis looks poised to continue growing thanks to key trends in pet adoption, spending on pets, and innovation in veterinary care. Livestock growth trends are also positive, supported by the growing global demand for protein.

Simply put, Pfizer and Zoetis have mastered how to develop drugs and bring them to market. It shouldn't be a surprise that Zoetis was once a part of Pfizer, but given how successful Zoetis has become, perhaps the student will one day teach the master.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Zoetis Inc. Stock Quote
Zoetis Inc.
ZTS
$165.33 (1.38%) $2.25
Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$49.92 (-0.93%) $0.47

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.